Yang Zhao1,2, Ziyi Chang1,3, Guizhen Zhao1, Haocheng Lu1, Wenhao Xiong4, Wenying Liang1, Huilun Wang1, Luis Villacorta1, Minerva T Garcia-Barrio1, Tianqing Zhu1, Yanhong Guo1, Yanbo Fan1,5, Lin Chang1, Francisco J Schopfer6, Bruce A Freeman6, Jifeng Zhang7, Y Eugene Chen8,9. 1. Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, 2800 Plymouth Road, Ann Arbor, MI, 48109, USA. 2. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA. 3. Department of Metabolism and Endocrinology, Central South University Second Xiangya Hospital, Changsha, Hunan, China. 4. Key Laboratory for Arteriosclerology of Hunan Province, University of South China, Hengyang, Hunan, China. 5. Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 6. Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA. 7. Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, 2800 Plymouth Road, Ann Arbor, MI, 48109, USA. jifengz@umich.edu. 8. Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, 2800 Plymouth Road, Ann Arbor, MI, 48109, USA. echenum@umich.edu. 9. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA. echenum@umich.edu.
Abstract
PURPOSE: Abdominal aortic aneurysm (AAA) is one of the leading causes of death in the developed world and is currently undertreated due to the complicated nature of the disease. Herein, we aimed to address the therapeutic potential of a novel class of pleiotropic mediators, specifically a new drug candidate, nitro-oleic acid (NO2-OA), on AAA, in a well-characterized murine AAA model. METHODS: We generated AAA using a mouse model combining AAV.PCSK9-D377Y induced hypercholesterolemia with angiotensin II given by chronic infusion. Vehicle control (PEG-400), oleic acid (OA), or NO2-OA were subcutaneously delivered to mice using an osmotic minipump. We characterized the effects of NO2-OA on pathophysiological responses and dissected the underlying molecular mechanisms through various in vitro and ex vivo strategies. RESULTS: Subcutaneous administration of NO2-OA significantly decreased the AAA incidence (8/28 mice) and supra-renal aorta diameters compared to mice infused with either PEG-400 (13/19, p = 0.0117) or OA (16/23, p = 0.0078). In parallel, the infusion of NO2-OA in the AAA model drastically decreased extracellular matrix degradation, inflammatory cytokine levels, and leucocyte/macrophage infiltration in the vasculature. Administration of NO2-OA reduced inflammation, cytokine secretion, and cell migration triggered by various biological stimuli in primary and macrophage cell lines partially through activation of the peroxisome proliferator-activated receptor-gamma (PPARγ). Moreover, the protective effect of NO2-OA relies on the inhibition of macrophage prostaglandin E2 (PGE2)-induced PGE2 receptor 4 (EP4) cAMP signaling, known to participate in the development of AAA. CONCLUSION: Administration of NO2-OA protects against AAA formation and multifactorial macrophage activation. With NO2-OA currently undergoing FDA approved phase II clinical trials, these findings may expedite the use of this nitro-fatty acid for AAA therapy.
PURPOSE: Abdominal aortic aneurysm (AAA) is one of the leading causes of death in the developed world and is currently undertreated due to the complicated nature of the disease. Herein, we aimed to address the therapeutic potential of a novel class of pleiotropic mediators, specifically a new drug candidate, nitro-oleic acid (NO2-OA), on AAA, in a well-characterized murine AAA model. METHODS: We generated AAA using a mouse model combining AAV.PCSK9-D377Y induced hypercholesterolemia with angiotensin II given by chronic infusion. Vehicle control (PEG-400), oleic acid (OA), or NO2-OA were subcutaneously delivered to mice using an osmotic minipump. We characterized the effects of NO2-OA on pathophysiological responses and dissected the underlying molecular mechanisms through various in vitro and ex vivo strategies. RESULTS: Subcutaneous administration of NO2-OA significantly decreased the AAA incidence (8/28 mice) and supra-renal aorta diameters compared to mice infused with either PEG-400 (13/19, p = 0.0117) or OA (16/23, p = 0.0078). In parallel, the infusion of NO2-OA in the AAA model drastically decreased extracellular matrix degradation, inflammatory cytokine levels, and leucocyte/macrophage infiltration in the vasculature. Administration of NO2-OA reduced inflammation, cytokine secretion, and cell migration triggered by various biological stimuli in primary and macrophage cell lines partially through activation of the peroxisome proliferator-activated receptor-gamma (PPARγ). Moreover, the protective effect of NO2-OA relies on the inhibition of macrophage prostaglandin E2 (PGE2)-induced PGE2 receptor 4 (EP4) cAMP signaling, known to participate in the development of AAA. CONCLUSION: Administration of NO2-OA protects against AAA formation and multifactorial macrophage activation. With NO2-OA currently undergoing FDA approved phase II clinical trials, these findings may expedite the use of this nitro-fatty acid for AAA therapy.
Authors: Gabriela Ambrozova; Hana Martiskova; Adolf Koudelka; Thorben Ravekes; Tanja K Rudolph; Anna Klinke; Volker Rudolph; Bruce A Freeman; Steven R Woodcock; Lukas Kubala; Michaela Pekarova Journal: Free Radic Biol Med Date: 2015-11-24 Impact factor: 7.376
Authors: Richard Y Cao; Tim St Amand; XinZhi Li; Sung-Hee Yoon; Carol P Wang; Hui Song; Takayuki Maruyama; Peter M Brown; David T Zelt; Colin D Funk Journal: Am J Pathol Date: 2012-05-15 Impact factor: 4.307
Authors: Volker Rudolph; Tanja K Rudolph; Francisco J Schopfer; Gustavo Bonacci; Steven R Woodcock; Marsha P Cole; Paul R S Baker; Ravi Ramani; Bruce A Freeman Journal: Cardiovasc Res Date: 2010-01-01 Impact factor: 10.787
Authors: Francis J Miller; William J Sharp; Xiang Fang; Larry W Oberley; Terry D Oberley; Neal L Weintraub Journal: Arterioscler Thromb Vasc Biol Date: 2002-04-01 Impact factor: 8.311
Authors: Tanja K Rudolph; Volker Rudolph; Martin M Edreira; Marsha P Cole; Gustavo Bonacci; Francisco J Schopfer; Steven R Woodcock; Andreas Franek; Michaela Pekarova; Nicholas K H Khoo; Alyssa H Hasty; Stephan Baldus; Bruce A Freeman Journal: Arterioscler Thromb Vasc Biol Date: 2010-02-18 Impact factor: 8.311
Authors: Luis Villacorta; Lin Chang; Sonia R Salvatore; Tomonaga Ichikawa; Jifeng Zhang; Danica Petrovic-Djergovic; Lingyun Jia; Harald Carlsen; Francisco J Schopfer; Bruce A Freeman; Y Eugene Chen Journal: Cardiovasc Res Date: 2013-01-17 Impact factor: 10.787
Authors: Nicholas K H Khoo; Marco Fazzari; Dionysios V Chartoumpekis; Lihua Li; Danielle Aparecida Guimaraes; Gavin E Arteel; Sruti Shiva; Bruce A Freeman Journal: Redox Biol Date: 2019-02-01 Impact factor: 11.799
Authors: M Lamas Bervejillo; J Bonanata; G R Franchini; A Richeri; J M Marqués; B A Freeman; F J Schopfer; E L Coitiño; B Córsico; H Rubbo; A M Ferreira Journal: Redox Biol Date: 2019-11-10 Impact factor: 11.799
Authors: Lorena Aranda-Caño; Raquel Valderrama; José Rafael Pedrajas; Juan C Begara-Morales; Mounira Chaki; María N Padilla; Manuel Melguizo; Francisco Javier López-Jaramillo; Juan B Barroso Journal: Antioxidants (Basel) Date: 2022-05-14
Authors: Hisashi Sawada (澤田悠); Hong S Lu (吕红); Lisa A Cassis; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2022-01-20 Impact factor: 8.311
Authors: Yao Du; Hui Zhang; Xiaoyan Nie; Yajun Qi; Shi Shi; Yingying Han; Wenchen Zhou; Chaoyong He; Lintao Wang Journal: Front Cardiovasc Med Date: 2022-08-22